Abstract
For many years, melanoma has been regarded as a single disease in terms of therapeutic considerations. The more recent identification of multiple molecular mechanisms underlying the development, progression, and prognosis of melanoma has led to a new paradigm for the management of this disease, has created new therapeutic opportunities, and has led to improved clinical outcomes. Such advances, however, are dependent upon methods that can reproducibly identify key molecular alterations within an individual tumor, define clinically relevant genetic subgroups of disease, and permit improved patient selection for targeted therapies.
Melanomas harboring genetic alterations of KIT have been demonstrated to constitute one such molecular subgroup of disease. In this chapter, we will discuss the biology of KIT in melanoma, review the rationale for and clinical data regarding KIT inhibition in melanomas harboring activating alterations of KIT, propose guidelines for the selection of patients for KIT inhibitor therapy, and, finally, present laboratory methods for KIT assessment in melanoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–2751
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365
Robert C, Flaherty K, Hersey P, Nathan P, CGarbe C, Milhem M, et al (2012) METRIC phase III study: efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol 30(suppl):(abstr LBA8509)
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–2147
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49(12):5230–5234, PMCID: 2634606
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602, PMCID: 2696133
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413
Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L et al (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63(18):5712–5715
Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J et al (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44(7):2876–2878
Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88(9):1403–1405, PMCID: 2741050
Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA et al (2008) Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49(1):23–27
Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–4346
Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14(21):6821–6828
Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L et al (1986) A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320(6061):415–421
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341–3351, PMCID: 553789
Woodman SE, Davies MA (2010) Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568–574
Huang EJ, Nocka KH, Buck J, Besmer P (1992) Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 3(3):349–362, PMCID: 275535
Ronnstrand L (2004) Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61(19–20):2535–2548
Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K (1995) Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85(3):641–649
Russell ES (1979) Hereditary anemias of the mouse: a review for geneticists. Adv Genet 20:357–459
Vincent S, Segretain D, Nishikawa S, Nishikawa SI, Sage J, Cuzin F et al (1998) Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: a Kit-KL interaction critical for meiosis. Development 125(22):4585–4593
Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA (1999) Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154(6):1643–1647, PMCID: 1876773
Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. Immunol Res 34(2):97–115, PMCID: 1490026
Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512):347–349
Phung B, Sun J, Schepsky A, Steingrimsson E, Ronnstrand L (2011) C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One 6(8):e24064, PMCID: 3161112
Hou L, Pavan WJ (2008) Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to Mitf? Cell Res 18(12):1163–1176
Cable J, Jackson IJ, Steel KP (1995) Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev 50(2–3):139–150
Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185):88–89
Spritz RA, Giebel LB, Holmes SA (1992) Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 50(2):261–269, PMCID: 1682440
Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55(1):185–192
Alexeev V, Yoon K (2006) Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126(5):1102–1110
Hachiya A, Sriwiriyanont P, Kobayashi T, Nagasawa A, Yoshida H, Ohuchi A et al (2009) Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair. J Pathol 218(1):30–39
Wang ZQ, Si L, Tang Q, Lin D, Fu Z, Zhang J et al (2009) Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet 84(5):672–677, PMCID: 2680999
Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13(11):2339–2347
Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52(2):197–201
Montone KT, van Belle P, Elenitsas R, Elder DE (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10(9):939–944
Lassam N, Bickford S (1992) Loss of c-kit expression in cultured melanoma cells. Oncogene 7(1):51–56
Shen SS, Zhang PS, Eton O, Prieto VG (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30(9):539–547
Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8):1398–1405, PMCID: 2362005
Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9):2005–2011
Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH et al (2008) Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99(5):734–740, PMCID: 2528157
Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369(9574):1731–1741
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134
Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170–2175
Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22):4514–4522
Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ (2004) Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 122(2):206–216
Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ (2006) BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37(5):520–527
Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121(2):257–264
Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452(1):27–32
Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H et al (2008) Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99(12):2065–2069, PMCID: 2607233
Ashida A, Takata M, Murata H, Kido K, Saida T (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124(4):862–868
Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al (2009) Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446–1456
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327–2334
Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L (1999) Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18(40):5546–5553
Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557–586
Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17(7):1684–1691
Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH et al (2011) KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 119(6):330–335
Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23(2):210–215
Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N (2010) c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29(2):227–236
Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al (2008) Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 14(23):7726–7732
Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al (2009) Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079–2085
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26(12):2046–2051
Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R (2010) Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy–case report and review of the literature. Dermatology 220(1):77–81
Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21(4):492–493
Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E et al (2010) Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23:14–26
Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P (2008) Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737–740
Zhu Y, Si L, Kong Y, Chi Z, Yuan X, Cui C, et al. (2009) Response to sunitinib in Chinese KIT – mutated metastatic mucosal melanoma. J Clin Oncol 27(abstract):e20017
Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC (2012) Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18(5):1457–1463
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB et al (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10):2202–2208
Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2011) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008–2014
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246
Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD et al (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15(22):6862–6870, PMCID: 2783687
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349
Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E et al (2008) Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21(4):476–484
Fletcher JA, Rubin BP (2007) KIT mutations in GIST. Curr Opin Genet Dev 17(1):3–7
Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C et al (2012) Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol 30(4):e37–e40
Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L et al (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102(8):1219–1223, PMCID: 2856012
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Carvajal, R.D., Hamid, O., Antonescu, C.R. (2014). Selecting Patients for KIT Inhibition in Melanoma. In: Thurin, M., Marincola, F. (eds) Molecular Diagnostics for Melanoma. Methods in Molecular Biology, vol 1102. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-727-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-62703-727-3_9
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-726-6
Online ISBN: 978-1-62703-727-3
eBook Packages: Springer Protocols